Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 10.00
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.50 (5.00%)
Open: 10.25
High: 10.25
Low: 10.25
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Change

10 Aug 2018 07:00

RNS Number : 4045X
Scancell Holdings Plc
10 August 2018
 

10 August 2018

 

Scancell Holdings Plc

("Scancell" or the "Company")

 

Board Change

 

 

Scancell Holdings Plc (AIM: SCLP) today announces that Kate Cornish-Bowden will be stepping down as Non-Executive Director as of 31 August 2018 after seven years on the Board of the Company.

 

Dr John Chiplin, Chairman of Scancell, commented:

 

"Kate has made an important contribution in guiding Scancell through its formative years during her time on the Board and in her role as chairman of the Remuneration Committee. We would like to thank her for her hard work and wish her all the best for the future."

 

 

For Further Information:

 

Scancell Holdings Plc

 

 

Dr John Chiplin, Chairman

 

+44 (0) 20 3727 1000

Dr Cliff Holloway, CEO

 

 

 

 

 

Panmure Gordon (UK) Limited

(Nominated Adviser and Corporate broker)

 

 

Freddy Crossley/Emma Earl

 

+44 (0) 20 7886 2500

 

 

 

FTI Consulting

Mo Noonan/Simon Conway

 

+44 (0) 20 3727 1000

 

 

About Scancell

 

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

 

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

 

· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

 

· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.

 

Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

 

· Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.

 

For further details, please see our website: www.scancell.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAFKLLBVVFBBBF
Date   Source Headline
28th Mar 20241:21 pmRNSScancell Appoints WG as Joint Broker
26th Mar 202412:22 pmRNSFirst iSCIB1+ patient dosed
14th Mar 202411:17 amRNSAppointment of Sath Nirmalananthan to the Board
12th Mar 20247:00 amRNSScancell Attendance at Upcoming Conferences
4th Mar 20247:00 amRNSPresenting at Next-Gen Immuno-Oncology Conference
20th Feb 20247:00 amRNSChange of Auditor
5th Feb 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSInterim Results
26th Jan 20247:00 amRNSNotice of Interim Results and Presentation
17th Jan 20241:46 pmRNSUpdate on SCOPE trial
28th Dec 20235:36 pmRNSHolding(s) in Company
27th Dec 202311:38 amRNSHolding(s) in Company
19th Dec 20237:00 amRNSResult of the Open Offer
6th Dec 202312:41 pmRNSPDMR Notification
1st Dec 20237:00 amRNSResults of Placing
30th Nov 20235:03 pmRNSProposed Capital Raise to raise approximately £6m
29th Nov 20232:35 pmRNSResult of AGM
28th Nov 20237:00 amRNSUpdate on SCOPE trial
10th Nov 20238:32 amRNSScancell to present at 20th SMR Congress
1st Nov 20237:00 amRNSScancell to present at 38th Annual SITC meeting
31st Oct 202312:00 pmRNSNotice of AGM
31st Oct 20237:00 amRNSResults for the Year Ended 30 April 2023
20th Oct 20237:00 amRNSUpdate on Final Results
18th Oct 20237:00 amRNSScancell to speak at World Vaccine Congress Europe
17th Oct 20237:00 amRNSBlock Listing Six Monthly Return
11th Oct 20237:00 amRNSChange of Date for Final Results
3rd Oct 20237:00 amRNSNotice of Final Results and Investor Presentation
19th Sep 20237:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
14th Sep 20237:00 amRNSScancell to present three posters at ICI
7th Sep 20237:00 amRNSScancell Appoints Head of Business Development
29th Aug 20237:00 amRNSScancell Appoints Sath Nirmalananthan as CFO
31st Jul 20237:00 amRNSModi-1 trial open for expansion in CPI combination
13th Jul 20239:14 amRNSExtension of exercise period for CEO share options
10th Jul 20237:00 amRNSPipeline strategy and business update
2nd Jun 20237:00 amRNSScancell to Present Modi-1 Data at ASCO
21st Apr 20237:00 amRNSIssue of share options to Non-Executive Directors
18th Apr 20237:00 amRNSModiFY Phase 1/2 poster presentation at AACR 2023
17th Apr 20237:00 amRNSBlock Listing Application to AIM
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank (SVB)
21st Feb 20239:05 amRNSSecond Price Monitoring Extn
21st Feb 20239:00 amRNSPrice Monitoring Extension
21st Feb 20237:00 amRNSEncouraging early efficacy data from ModiFY trial
13th Feb 20237:00 amRNSPositive response in COVIDITY trial
8th Feb 20237:00 amRNSIssue of Equity
1st Feb 20237:00 amRNSDr Jean-Michel Cosséry appointed as Chairman
25th Jan 20237:00 amRNSInterim Results
18th Jan 20237:00 amRNSNotice of Interim Results
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20223:18 pmRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.